TABLE 2.
Susceptibility profiles of ESBL-producing E. coli isolates according to specimen source, interpreted using 2010 CLSI breakpoints
| Isolate sourcea | No. (%)b |
|||
|---|---|---|---|---|
| Total | Susceptible result for 1 drug | Susceptible result for ≥2 drugs | Resistant | |
| Blood | 34 | 2 (5.9) | 9 (26.5) | 23 (67.6) |
| Bronchial secretion or sputum | 13 | 2 (15.4) | 2 (15.4) | 9 (69.2) |
| Surgical or tissue specimen | 15 | 3 (20.0) | 4 (26.7) | 8 (53.3) |
| Urine | 537 | 86 (16.0) | 140 (26.1) | 311 (57.9) |
| Unknown | 30 | 2 (6.7) | 12 (40.0) | 16 (53.3) |
| Total | 638 | 95 (14.9) | 170 (26.7) | 373 (58.5) |
a
Throat, skin, rectal, and genital swabs (n = 9) are not listed.
b
The drugs evaluated were aztreonam, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, and cefepime.